UTI Treatment Leads to Fatal Drug Interaction in a Schizophrenia Patient
This case is the first to describe a fatal outcome with such an interaction.
This case is the first to describe a fatal outcome with such an interaction.
A qualitative study published in the journal Psychiatry Services aimed to identify the various coping strategies used by patients recovering from schizophrenia, adding to the somewhat limited information available about how individuals manage their schizophrenia. Researchers at the Los Angeles Department of Veterans Affairs Healthcare System enrolled 20 patients with a diagnosis of schizophrenia who experienced at…
A study published in Psychopharmacology concludes that stable, non-acute but symptomatic patients taking oral antipsychotic monotherapy may experience clinically meaningful improvement in symptoms, functioning, and treatment satisfaction after direct switch to paliperidone palmitate once-monthly injection. A team of researchers conducted a post-hoc analysis of a prospective, interventional, single-arm, international, multicenter, open-label, 6-month study to investigate the safety, tolerability, and…
Pyrotherapy is “the use of fever to treat disease.”1 This ancient modality can be traced as far back as Hippocrates, who noted the beneficial effects of malaria on epilepsy. Subsequently, Galen noticed that fever had a beneficial effect on psychiatric illness. Other early physicians to make this connection were Pinel (1745-1826), Esquirol (1772-1840), Briquet (1796-1881),…
Supplementation with taurine, the additive found in many energy drinks, may improve the symptoms in young people suffering a first episode of psychosis (FEP), according to a new study presented at the International Early Psychosis Association (IEPA) meeting. Taurine, an amino acid naturally occurring in the body, exhibits an inhibitory neuro-modulatory effect in the nervous…
No significant difference in weight loss for obese patients treated with exenatide, placebo
Not only is it difficult to diagnose patients who suffer from both of these disorders, treatment is challenging due to the controversial evidence regarding appropriate therapy.
Periods of relapse often lead to detrimental effects for patients as well as caregivers, therefore it is important to prevent relapse and increase remission time as much as possible.
Sunovion announced the publication of data from a randomized, double-blind, placebo-controlled study that evaluated the efficacy of low-dose Latuda (lurasidone HCl) 20mg daily in adults with schizophrenia, and the effect of dose escalation in adults who demonstrated inadequate initial response to standard dose Latuda.
Researchers investigated the efficacy of individual antidepressants in the treatment of depressive and negative symptoms associated with schizophrenia.